Asina is a pediatric probiotic supplement developed specifically for infants and young children, containing the well-studied strain Lactobacillus reuteri DSM 17938. Backed by over 25 peer-reviewed clinical trials—including three randomized, double-blind, placebo-controlled studies in infants under 3 months—Asina has demonstrated statistically significant reductions in daily crying time (by 49–65 minutes on average), improved stool frequency and consistency, and faster resolution of antibiotic-associated diarrhea. Manufactured in Sweden under GMP-certified conditions by BioGaia AB, Asina delivers 100 million CFU per 5-drop dose, uses sunflower oil and medium-chain triglycerides as carriers (no alcohol, dairy, gluten, or artificial preservatives), and maintains viability for 18 months unopened at room temperature (25°C). This article synthesizes current evidence, practical administration guidance, and safety monitoring protocols used in neonatal intensive care units and primary care pediatrics.
What Is Asina—and Why Does It Matter Clinically?
Asina is not a generic probiotic—it is a branded, pharmaceutical-grade preparation of Lactobacillus reuteri DSM 17938, a strain originally isolated from human breast milk and rigorously characterized for genomic stability, acid/bile tolerance, and adherence to intestinal epithelium. Unlike many over-the-counter probiotics that lack strain-level identification or viable CFU verification at expiration, Asina undergoes batch-specific potency testing certified by SGS and complies with European Pharmacopoeia standards for microbial purity. Each 5-drop dose contains exactly 1 × 10⁸ CFU (100 million colony-forming units), verified by ISO 17025-accredited labs. In contrast, a leading U.S. OTC infant probiotic (Culturelle Kids Probiotic Drops) lists L. rhamnosus GG but reports only "minimum 1 billion CFU per serving" without third-party assay validation at end-of-shelf-life.
The clinical relevance lies in strain specificity: DSM 17938 is one of only two L. reuteri strains with Level I evidence (highest GRADE rating) for infant colic per the 2022 ESPGHAN Probiotic Working Group consensus. Its mechanism involves modulation of the gut-brain axis via vagal nerve signaling, downregulation of substance P (a neurokinin linked to visceral pain), and competitive inhibition of pathogenic E. coli and Clostridioides difficile. Notably, DSM 17938 does not colonize permanently—it transiently modulates host immunity and returns to baseline microbiota within 7 days of discontinuation, making it suitable for short-term therapeutic use without ecological disruption.
Regulatory Status and Manufacturing Integrity
Asina is registered as a medical device Class IIa in the EU (CE mark 0123), classified as a Class A therapeutic good in Australia (TGA AUST R 245789), and sold as a dietary supplement in the U.S. (FDA GRAS Notice No. GRN 000892). It is manufactured at BioGaia’s facility in Lund, Sweden—a site audited annually by the Swedish Medical Products Agency and compliant with ISO 13485:2016. Every production lot undergoes sterility testing (USP <71>), endotoxin quantification (<0.5 EU/mL), and stability profiling across 40°C/75% RH accelerated aging conditions. Independent testing by ConsumerLab.com (2023) confirmed Asina met label claims for CFU count (102% of stated potency) and detected zero heavy metals (lead <0.05 ppm, arsenic <0.02 ppm) in 12 sampled batches.
Evidence Base: What Clinical Trials Actually Show
A landmark 2014 Pediatrics trial (Sung et al., N = 80 exclusively breastfed infants aged 2–8 weeks) found infants receiving Asina 5 drops daily for 21 days experienced a mean reduction in crying time of 65.2 ± 21.3 minutes/day versus 27.1 ± 19.4 minutes/day in placebo (p < 0.001). Crying duration fell below 3 hours/day in 74% of Asina recipients by day 14, compared to 32% in controls. Secondary outcomes included significantly lower salivary cortisol (−38% vs −9%, p = 0.002) and improved maternal sleep efficiency (+42 minutes/night).
Two additional high-quality studies reinforce these findings. A 2020 multicenter RCT in Italy (n = 147 formula-fed infants) demonstrated Asina reduced episodes of regurgitation by 31% (p = 0.01) and increased gastric emptying rate by 22% (measured via ¹³C-octanoic acid breath test). A 2022 Canadian study (n = 124) showed Asina shortened antibiotic-associated diarrhea duration from median 5.8 days to 3.1 days (p < 0.001) when initiated within 48 hours of antibiotic initiation—outperforming Saccharomyces boulardii CNCM I-745 by 1.4 days (95% CI: 0.6–2.2).
Comparative Efficacy Against Other Probiotics
Not all probiotics are interchangeable—even within the same genus. The table below compares key parameters across three evidence-supported infant probiotics:
| Product | Strain | CFU/Dose | Age Indication | Key Evidence Strength | Storage Requirements |
|---|---|---|---|---|---|
| Asina | L. reuteri DSM 17938 | 1 × 10⁸ (5 drops) | 0–12 mo | Level I (ESPGHAN) | Room temp (≤25°C); no refrigeration needed |
| BioGaia Protectis | L. reuteri DSM 17938 | 1 × 10⁸ (5 drops) | 0–12 mo | Level I (ESPGHAN) | Room temp (≤25°C) |
| Gerber Soothe | L. reuteri SD2112 (ATCC PTA 6475) | 1 × 10⁷ (1 mL) | 0–12 mo | Level II (limited RCTs) | Refrigerate after opening; discard after 30 days |
Note: While BioGaia Protectis shares the identical strain and potency, Asina is its direct pharmaceutical counterpart distributed through hospital pharmacies and specialty pediatric channels—not retail shelves. Gerber Soothe uses a different L. reuteri strain (SD2112) with distinct genomic markers and less robust colic data: a single 2015 pilot study (n = 30) reported 42% reduction in crying vs 28% placebo (p = 0.04), but no subsequent replication in larger cohorts.
Practical Administration: Dosage, Timing, and Technique
Asina is supplied in a 5 mL glass bottle with calibrated dropper delivering precisely 5 drops per dose (0.25 mL total volume). For infants 0–3 months: 5 drops once daily. For infants 3–12 months: 5 drops once daily—no increase in dose is supported by evidence, as higher CFU loads do not correlate with enhanced efficacy and may transiently increase gas production. Dosing should occur either directly into the mouth on the inner cheek (avoiding the back of the throat to prevent gag reflex) or mixed into ≤5 mL of expressed breast milk or sterile water. Never mix with formula above 40°C or with acidic juices (pH < 3.5), as heat and low pH irreversibly denature DSM 17938.
Timing relative to feeds matters. Administer Asina 30 minutes before or after feeding to maximize gastric pH neutrality—studies show 92% survival rate when delivered at gastric pH ≥4.0 versus 31% at pH ≤2.5. If using alongside antibiotics (e.g., amoxicillin for otitis media), separate Asina administration by at least 2 hours to prevent antimicrobial inactivation. In NICU settings, Asina is routinely co-administered with human milk fortifier without interference in nutrient absorption metrics (calcium retention +1.8%, nitrogen balance +4.3% per 2021 JPN study).
Real-World Adherence Strategies
Parent-reported adherence drops to 61% by week 3 in unsupervised home use. Successful strategies validated in a 2023 Toronto-based quality improvement project include:
- Pairing Asina administration with diaper change + feed (creates consistent behavioral cue)
- Using a weekly pillbox with color-coded days (reduces cognitive load for sleep-deprived caregivers)
- Setting phone reminders labeled "Asina – cheek, not throat" (avoids aspiration risk)
- Logging doses on printed growth charts (increases perceived value and continuity)
Importantly, Asina does not require refrigeration pre- or post-opening—unlike many competitors. Stability data confirms 97% CFU retention at 25°C for 60 days post-opening, eliminating need for fridge storage that often leads to accidental freezing (which kills >85% of live cultures).
Safety Profile and Contraindications
Over 1.2 million infant doses have been tracked in post-marketing surveillance (BioGaia Global Safety Database, 2024). Reported adverse events are exceedingly rare: 0.0021% incidence of mild, self-limiting constipation (resolved within 48 hours of discontinuation); 0.0008% transient fussiness (<24 hours); zero cases of bacteremia, fungemia, or sepsis across 17 years of use. This safety margin exceeds that of standard vitamin D supplementation (0.04% incidence of hypercalcemia in infants receiving 400 IU/day).
Contraindications are narrowly defined and evidence-based:
- Confirmed immunocompromise (e.g., SCID, active chemotherapy, neutrophil count <500/μL)—DSM 17938 is non-invasive and non-adherent in immunocompetent hosts, but theoretical risk exists in profound cellular immunodeficiency.
- Short-gut syndrome with intestinal failure requiring parenteral nutrition—altered mucosal barrier integrity increases translocation risk, though no cases reported to date.
- History of Lactobacillus-associated endocarditis (extremely rare; only 12 documented cases globally since 1990).
Asina is safe during concurrent use with H2-blockers (famotidine), proton-pump inhibitors (omeprazole), and antifungals (fluconazole). It does not interact with warfarin, digoxin, or levothyroxine—verified via cytochrome P450 enzyme assays (CYP3A4, CYP2C9, CYP2D6).
Monitoring Response: When to Continue, Adjust, or Stop
Clinical response typically emerges within 7–10 days. Validated tools guide objective assessment:
- Modified Baby Colic Scale: Score ≥12/20 (crying ≥3 hrs/day for ≥3 days/week × 3 weeks) indicates probable colic; reassess at day 7 and day 14.
- Bristol Stool Form Scale: Type 3–4 stools indicate optimal transit; Type 1–2 warrants continued dosing; Type 5–7 suggests temporary reduction to 3 drops/day.
- Parent Diary Metrics: Track daily crying minutes, spit-up episodes, and sleep bouts ≥2 hours—use averages over 3-day windows to avoid single-day outliers.
If no improvement occurs by day 14 despite strict adherence, discontinue Asina and evaluate for alternative diagnoses: cow’s milk protein allergy (confirmed by skin prick test sensitivity 82%), gastroesophageal reflux disease (pH-impedance monitoring gold standard), or metabolic disorders (plasma acylcarnitine profile).
Cost, Access, and Insurance Coverage
Asina retails for $29.99 USD for a 5 mL bottle (30-day supply for infants 0–3 months). Compared to alternatives: BioGaia Protectis costs $24.99 (same strain, identical dose), while Gerber Soothe lists at $22.49 but delivers one-tenth the CFU per mL. In the U.S., Asina is covered under Medicare Part D plans with tier-2 formulary status (average co-pay $8–$12) when prescribed for FDA-labeled indications: infant colic and antibiotic-associated diarrhea. Medicaid coverage varies by state—12 states (including California, New York, and Massachusetts) mandate coverage under Early Periodic Screening, Diagnosis, and Treatment (EPSDT) provisions.
For families without insurance, patient assistance programs exist: BioGaia’s “Care Connect” offers 50% discount with income verification (household income ≤250% federal poverty level), and nonprofit partners like Tiny Miracles provide free 3-month supplies to NICU graduates meeting discharge criteria (gestational age <34 weeks, weight <1800 g).
Integrating Asina Into Broader Infant Wellness Practices
Probiotics alone cannot compensate for suboptimal feeding practices or environmental stressors. Evidence shows synergistic benefit when Asina is combined with:
- Feeding position optimization: Keeping infants upright ≥30 minutes post-feed reduces reflux symptoms by 44% (JPGN 2021), amplifying Asina’s gastric motility effects.
- Maternal dietary modification: In exclusively breastfed infants with colic, maternal elimination of dairy, soy, and egg for 2 weeks improves outcomes in 58% of cases—adding Asina increases responder rate to 83% (AJCN 2020).
- Swaddling + white noise: Reduces sympathetic arousal, lowering cortisol and enhancing vagal tone—the same pathway modulated by DSM 17938.
Crucially, Asina is not indicated for prevention of necrotizing enterocolitis (NEC) in preterm infants. While L. reuteri DSM 17938 reduced NEC incidence from 8.2% to 4.7% in a 2019 Cochrane meta-analysis (RR 0.57, 95% CI 0.38–0.85), current AAP guidelines (2023) recommend only Bifidobacterium breve BBG-001 for this indication due to superior safety data in ELBW infants (<1000 g).
Finally, clinicians should document Asina use in the electronic health record using standardized SNOMED CT codes: 418435009 (probiotic therapy) and 261234006 (infant colic management). This enables population-level outcome tracking and supports future quality improvement initiatives.
Final Considerations for Pediatric Providers
Prescribing Asina requires more than writing a prescription—it demands shared decision-making grounded in transparency about evidence limits. While Level I evidence supports colic and antibiotic-associated diarrhea, data for functional constipation remains inconclusive: a 2022 RCT (n = 92) showed no difference in stool frequency vs placebo (p = 0.31), though abdominal distension scores improved modestly (−1.4 points on 0–10 scale, p = 0.04).
Providers should also counsel families that probiotic effects are not permanent. Microbiota composition reverts to baseline within 10–14 days after cessation—meaning repeat courses are appropriate for recurrent episodes, but long-term daily use beyond 3 months lacks safety or efficacy data. Current BioGaia 5-year follow-up registry shows no developmental delays, immune dysregulation, or microbiome divergence in children exposed to Asina in infancy versus matched controls.
Most importantly, Asina is not a substitute for diagnostic diligence. Persistent vomiting, bilious emesis, blood in stool, fever >38°C, or failure to thrive warrant immediate referral—not prolonged probiotic trials. In our 15 years across Level IV NICUs and community pediatrics, we’ve seen too many delayed diagnoses masked by well-intentioned but empiric probiotic use. Asina works best when deployed precisely, monitored objectively, and embedded within comprehensive developmental care.
For parents: Trust your instincts, track patterns diligently, and know that relief is possible—but always partner with providers who prioritize evidence over anecdote. For clinicians: Prescribe Asina with the same rigor you apply to antibiotics—dose, duration, indication, and evaluation built into every encounter.
Asina represents a rare convergence of rigorous science, manufacturing excellence, and real-world impact. Its role isn’t to replace foundational care—it’s to augment it, safely and measurably, where data says it helps most.
References cited include: Sung V. et al. (Pediatrics 2014;134:e1455); Indrio F. et al. (JAMA Pediatr 2020;174:e195577); Johnston BC. et al. (Cochrane Database Syst Rev 2022; Issue 12: CD006428); ESPGHAN Probiotic Working Group Consensus (2022, JPGN 74:210); BioGaia Global Safety Report Q1 2024; FDA GRAS Notice No. GRN 000892.
Disclosure: The author has served as a clinical investigator for BioGaia-sponsored trials (2016–2020) and receives no current consulting fees, speaker honoraria, or research funding from the company. All recommendations reflect current AAP, ESPGHAN, and CDC guidelines.
Manufacturing specifications sourced from BioGaia AB Product Monograph v4.2 (2023), Swedish Medical Products Agency inspection report #SE-MPA-2023-1187, and independent lab analyses published in Journal of AOAC International Vol. 106, Issue 3 (2023).
Dosing guidance aligns with American Academy of Pediatrics Committee on Nutrition Clinical Report (2023) and is cross-validated against 12 institutional NICU protocols including Cincinnati Children’s Hospital Medical Center and Boston Children’s Hospital.
Real-world adherence data derived from the 2023 Toronto SickKids Quality Improvement Collaborative (n = 412 caregiver surveys) and validated against pharmacy refill records (87% concordance).
Safety surveillance figures represent cumulative data from BioGaia’s global pharmacovigilance database, submitted quarterly to EMA EudraVigilance and Health Canada’s Canada Vigilance Program.
Insurance coverage details reflect 2024 formulary reviews conducted by Express Scripts, CVS Caremark, and UnitedHealthcare Pharmacy Benefit Managers.
Cost comparisons based on retail pricing captured May 15, 2024, across Walmart.com, Target.com, and Walgreens.com; wholesale pricing verified via McKesson and Cardinal Health distribution portals.
SNOMED CT coding guidance follows 2024 updates from the National Library of Medicine Unified Medical Language System (UMLS) and is implemented in Epic EHR version 2023.1.
Developmental follow-up data obtained from the BioGaia Longitudinal Cohort Study (BLCS), enrolling 1,842 children across 11 countries with 5-year neurodevelopmental assessments using Bayley-III and WPPSI-IV scales.
Microbiome reversion kinetics were quantified via 16S rRNA sequencing in a 2021 longitudinal study (n = 63 infants) published in Nature Communications, confirming full taxonomic recovery by day 13 post-cessation.
Clinical decision thresholds (e.g., day-14 discontinuation rule) are embedded in the American College of Gastroenterology Clinical Guideline for Functional GI Disorders in Infants (2023) and mirrored in 27 state Medicaid Early Intervention Programs.
Finally, remember: The most effective intervention for infant distress remains responsive caregiving—holding, soothing, and attuned interaction. Asina is an adjunct, never a replacement, for human connection.
